Technology

Mustang Bio

$4.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (+4.20%) Today
+$0.09 (+1.91%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Mustang Bio and other stocks, options, and ETFs commission-free!

About MBIO

Mustang Bio, Inc. Common Stock, also called Mustang Bio, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA. The listed name for MBIO is Mustang Bio, Inc. Common Stock.

CEO
Manuel Litchman
Employees
51
Headquarters
Worcester, Massachusetts
Founded
2015
Market Cap
302.51M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.77M
High Today
$4.83
Low Today
$4.47
Open Price
$4.66
Volume
2.54M
52 Week High
$4.87
52 Week Low
$1.78

Collections

MBIO Earnings

-$0.42
-$0.28
-$0.14
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

EPD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure